Menu
GeneBe

TTR

transthyretin, the group of Gla domain containing

Basic information

Region (hg38): 18:31557008-31598833

Previous symbols: [ "PALB", "CTS1" ]

Links

ENSG00000118271NCBI:7276OMIM:176300HGNC:12405Uniprot:P02766AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • heart conduction disease (Strong), mode of inheritance: AD
  • familial amyloid neuropathy (Strong), mode of inheritance: AD
  • familial amyloid neuropathy (Supportive), mode of inheritance: AD
  • ATTRV122I amyloidosis (Supportive), mode of inheritance: AD
  • familial amyloid neuropathy (Definitive), mode of inheritance: AD
  • hereditary ATTR amyloidosis (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Amyloidosis, hereditary, transthyretin-related; Hyperthyroxinemia, dystransthyretinemicADCardiovascular; Endocrine; Gastrointestinal; NeurologicIn Familial transthyretin amyloidosis, surveillance for cardiovascular sequelae (which can include arrhythmias), and earlier treatment (eg, pacemaker) can be beneficial, and liver transplantation may be beneficial especially early in the disease course; Therapies involving transthyretin stabilization, RNA interference, or inhibtion of the hepatic production of transthyretin protein may be beneficial, especially in early stages of disease; In Dystransthyretinemic hyperthyroxinemia, diagnosis may be important in order to avoid unecessary treatment (eg, thyroid ablation)Endocrine; Gastrointestinal; Musculoskeletal; Neurologic; Ophthalmologic; Renal13320157; 7417777; 6801514; 3229002; 1979335; 7839813; 8309582; 8784093; 8579098; 9017939; 10523220; 10869060; 11261421; 11385707; 11940682; 14640030; 14986482; 15249622; 15820680; 16357452; 15725588; 17554795; 19075702; 17200500; 18022643; 20301373; 22094129; 22843282; 23193944; 23483184; 23834402; 23901247; 23931808; 23984729; 23984729; 23993291; 24000164; 24023270; 24053266; 29972757

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the TTR gene.

  • Amyloidogenic transthyretin amyloidosis (264 variants)
  • Cardiovascular phenotype (134 variants)
  • not provided (108 variants)
  • not specified (54 variants)
  • Cardiomyopathy (31 variants)
  • Charcot-Marie-Tooth disease (29 variants)
  • Amyloidogenic transthyretin amyloidosis;Hyperthyroxinemia, dystransthyretinemic;Carpal tunnel syndrome 1 (12 variants)
  • Hyperthyroxinemia, dystransthyretinemic;Carpal tunnel syndrome 1;Amyloidogenic transthyretin amyloidosis (9 variants)
  • Hyperthyroxinemia, dystransthyretinemic;Amyloidogenic transthyretin amyloidosis;Carpal tunnel syndrome 1 (9 variants)
  • AMYLOIDOSIS, LEPTOMENINGEAL, TRANSTHYRETIN-RELATED (4 variants)
  • Amyloidogenic transthyretin amyloidosis;Carpal tunnel syndrome 1;Hyperthyroxinemia, dystransthyretinemic (4 variants)
  • Tip-toe gait (3 variants)
  • TTR-related condition (3 variants)
  • Carpal tunnel syndrome 1;Amyloidogenic transthyretin amyloidosis;Hyperthyroxinemia, dystransthyretinemic (3 variants)
  • Inborn genetic diseases (2 variants)
  • Carpal tunnel syndrome 1;Hyperthyroxinemia, dystransthyretinemic;Amyloidogenic transthyretin amyloidosis (2 variants)
  • Hereditary amyloidosis (2 variants)
  • Hyperthyroxinemia, dystransthyretinemic (2 variants)
  • Anemia;Bone marrow hypocellularity;Pancytopenia (1 variants)
  • Hereditary ATTR amyloidosis (1 variants)
  • ATTRV122I amyloidosis (1 variants)
  • Amyloid Cardiomyopathy, Transthyretin-related (1 variants)
  • AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED, MODIFIER OF (1 variants)
  • Heart failure (1 variants)
  • Carpal tunnel syndrome (1 variants)
  • Brugada syndrome (1 variants)
  • TTR-related disorders (1 variants)
  • Hypertrophic cardiomyopathy 1 (1 variants)
  • Conduction disorder of the heart (1 variants)
  • Amyloidogenic transthyretin amyloidosis;Hyperthyroxinemia, dystransthyretinemic;Carpal tunnel syndrome (1 variants)
  • Primary familial hypertrophic cardiomyopathy (1 variants)
  • TRANSTHYRETIN POLYMORPHISM (1 variants)
  • Hypertrophic cardiomyopathy (1 variants)
  • Amyloidosis (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the TTR gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
42
clinvar
1
clinvar
43
missense
39
clinvar
54
clinvar
74
clinvar
3
clinvar
170
nonsense
3
clinvar
3
start loss
0
frameshift
6
clinvar
6
inframe indel
1
clinvar
5
clinvar
6
splice donor/acceptor (+/-2bp)
7
clinvar
7
splice region
8
9
17
non coding
5
clinvar
23
clinvar
6
clinvar
34
Total 40 54 100 68 7

Highest pathogenic variant AF is 0.00467

Variants in TTR

This is a list of pathogenic ClinVar variants found in the TTR region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
18-31591160-A-T Familial amyloid neuropathy • Hyperthyroxinemia, dystransthyretinemic;Familial amyloid neuropathy;Carpal tunnel syndrome 1 Benign/Likely benign (Jan 29, 2024)744399
18-31591801-G-T Familial amyloid neuropathy Conflicting classifications of pathogenicity (Apr 27, 2017)890861
18-31591842-G-A Familial amyloid neuropathy • Hyperthyroxinemia, dystransthyretinemic;Carpal tunnel syndrome 1;Familial amyloid neuropathy Uncertain significance (May 19, 2022)326544
18-31591857-C-T not specified Likely benign (May 15, 2017)509654
18-31591888-C-T Hyperthyroxinemia, dystransthyretinemic;Familial amyloid neuropathy;Carpal tunnel syndrome 1 • Cardiovascular phenotype Conflicting classifications of pathogenicity (Jul 08, 2021)1230561
18-31591900-A-G Cardiovascular phenotype Conflicting classifications of pathogenicity (Aug 17, 2022)1235184
18-31591902-G-C Cardiovascular phenotype Uncertain significance (Feb 10, 2020)495839
18-31591908-T-G Familial amyloid neuropathy Likely benign (Jul 14, 2023)2914555
18-31591910-CTCA-C Familial amyloid neuropathy • Hyperthyroxinemia, dystransthyretinemic;Familial amyloid neuropathy;Carpal tunnel syndrome 1 Uncertain significance (Nov 27, 2023)658582
18-31591911-T-C Familial amyloid neuropathy • Cardiovascular phenotype Likely benign (Nov 05, 2023)749124
18-31591910-C-CTCA Familial amyloid neuropathy • Hyperthyroxinemia, dystransthyretinemic;Carpal tunnel syndrome 1;Familial amyloid neuropathy • Cardiovascular phenotype Uncertain significance (Sep 23, 2023)326545
18-31591913-A-T Familial amyloid neuropathy • Charcot-Marie-Tooth disease • Cardiovascular phenotype Uncertain significance (Dec 06, 2023)803480
18-31591914-T-A Familial amyloid neuropathy Uncertain significance (Aug 04, 2021)1471008
18-31591915-C-G Familial amyloid neuropathy Uncertain significance (Oct 20, 2021)284011
18-31591915-C-T Familial amyloid neuropathy • Carpal tunnel syndrome 1;Hyperthyroxinemia, dystransthyretinemic;Familial amyloid neuropathy • Cardiovascular phenotype Uncertain significance (Feb 10, 2023)940630
18-31591916-G-A not specified • Cardiovascular phenotype • Familial amyloid neuropathy • Cardiomyopathy • Charcot-Marie-Tooth disease • TTR-related disorder Conflicting classifications of pathogenicity (Jan 27, 2024)181697
18-31591923-C-T Familial amyloid neuropathy Likely benign (Jan 21, 2021)1673536
18-31591926-C-T Familial amyloid neuropathy • Cardiovascular phenotype Benign/Likely benign (Feb 14, 2023)1260782
18-31591927-C-T Familial amyloid neuropathy Uncertain significance (Dec 06, 2017)245725
18-31591936-G-T Familial amyloid neuropathy • Cardiovascular phenotype Uncertain significance (Aug 22, 2022)579863
18-31591937-C-A Familial amyloid neuropathy Uncertain significance (Dec 11, 2019)857014
18-31591937-C-T Familial amyloid neuropathy Uncertain significance (Feb 06, 2022)2093779
18-31591939-G-A Familial amyloid neuropathy • Familial amyloid neuropathy;Carpal tunnel syndrome 1;Hyperthyroxinemia, dystransthyretinemic Uncertain significance (Oct 09, 2023)1423499
18-31591942-C-T Familial amyloid neuropathy • Familial amyloid neuropathy;Hyperthyroxinemia, dystransthyretinemic;Carpal tunnel syndrome 1 Benign/Likely benign (Nov 14, 2022)1119640
18-31591947-A-G Familial amyloid neuropathy Likely benign (Nov 29, 2022)2110740

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
TTRprotein_codingprotein_codingENST00000237014 47286
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.5160.469125741031257440.0000119
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.015783.00.6870.00000464934
Missense in Polyphen1728.7830.59064343
Synonymous0.4333033.20.9040.00000190312
Loss of Function1.9416.220.1613.52e-769

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.00002890.0000289
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.00002640.0000176
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain. {ECO:0000269|PubMed:3714052}.;
Disease
DISEASE: Amyloidosis, transthyretin-related (AMYL-TTR) [MIM:105210]: A hereditary generalized amyloidosis due to transthyretin amyloid deposition. Protein fibrils can form in different tissues leading to amyloid polyneuropathies, amyloidotic cardiomyopathy, carpal tunnel syndrome, systemic senile amyloidosis. The disease includes leptomeningeal amyloidosis that is characterized by primary involvement of the central nervous system. Neuropathologic examination shows amyloid in the walls of leptomeningeal vessels, in pia arachnoid, and subpial deposits. Some patients also develop vitreous amyloid deposition that leads to visual impairment (oculoleptomeningeal amyloidosis). Clinical features include seizures, stroke-like episodes, dementia, psychomotor deterioration, variable amyloid deposition in the vitreous humor. {ECO:0000269|PubMed:10036587, ECO:0000269|PubMed:10071047, ECO:0000269|PubMed:10211412, ECO:0000269|PubMed:10436378, ECO:0000269|PubMed:10439117, ECO:0000269|PubMed:10611950, ECO:0000269|PubMed:10627135, ECO:0000269|PubMed:10694917, ECO:0000269|PubMed:10842705, ECO:0000269|PubMed:10842718, ECO:0000269|PubMed:10882995, ECO:0000269|PubMed:11243784, ECO:0000269|PubMed:11445644, ECO:0000269|PubMed:11866053, ECO:0000269|PubMed:12050338, ECO:0000269|PubMed:12403615, ECO:0000269|PubMed:12557757, ECO:0000269|PubMed:12771253, ECO:0000269|PubMed:1301926, ECO:0000269|PubMed:1351039, ECO:0000269|PubMed:1362222, ECO:0000269|PubMed:1436517, ECO:0000269|PubMed:1517749, ECO:0000269|PubMed:1520326, ECO:0000269|PubMed:1520336, ECO:0000269|PubMed:15214015, ECO:0000269|PubMed:15217993, ECO:0000269|PubMed:1544214, ECO:0000269|PubMed:15478468, ECO:0000269|PubMed:1570831, ECO:0000269|PubMed:15735344, ECO:0000269|PubMed:16185074, ECO:0000269|PubMed:1656975, ECO:0000269|PubMed:16627944, ECO:0000269|PubMed:1734866, ECO:0000269|PubMed:17453626, ECO:0000269|PubMed:17503405, ECO:0000269|PubMed:17577687, ECO:0000269|PubMed:17635579, ECO:0000269|PubMed:19167329, ECO:0000269|PubMed:1932142, ECO:0000269|PubMed:2046936, ECO:0000269|PubMed:2161654, ECO:0000269|PubMed:23317988, ECO:0000269|PubMed:2363717, ECO:0000269|PubMed:2891727, ECO:0000269|PubMed:3022108, ECO:0000269|PubMed:3135807, ECO:0000269|PubMed:3722385, ECO:0000269|PubMed:3818577, ECO:0000269|PubMed:6487335, ECO:0000269|PubMed:6583672, ECO:0000269|PubMed:6651852, ECO:0000269|PubMed:7655883, ECO:0000269|PubMed:7850982, ECO:0000269|PubMed:7910950, ECO:0000269|PubMed:7914929, ECO:0000269|PubMed:7923855, ECO:0000269|PubMed:8019560, ECO:0000269|PubMed:8038017, ECO:0000269|PubMed:8081397, ECO:0000269|PubMed:8095302, ECO:0000269|PubMed:8133316, ECO:0000269|PubMed:8257997, ECO:0000269|PubMed:8352764, ECO:0000269|PubMed:8382610, ECO:0000269|PubMed:8428915, ECO:0000269|PubMed:8579098, ECO:0000269|PubMed:8990019, ECO:0000269|PubMed:9066351, ECO:0000269|PubMed:9605286, ECO:0000269|PubMed:9733771, ECO:0000269|Ref.90}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Hyperthyroxinemia, dystransthyretinemic (DTTRH) [MIM:145680]: A condition characterized by elevation of total and free thyroxine in healthy, euthyroid persons without detectable binding protein abnormalities. {ECO:0000269|PubMed:1979335}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Carpal tunnel syndrome 1 (CTS1) [MIM:115430]: A condition characterized by entrapment of the median nerve within the carpal tunnel. Symptoms include burning pain and paresthesias involving the ventral surface of the hand and fingers which may radiate proximally. Impairment of sensation in the distribution of the median nerve and thenar muscle atrophy may occur. This condition may be associated with repetitive occupational trauma, wrist injuries, amyloid neuropathies, rheumatoid arthritis. {ECO:0000269|PubMed:8309582}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Thyroid hormone synthesis - Homo sapiens (human);Signaling by GPCR;Neutrophil degranulation;Signal Transduction;Metabolism of fat-soluble vitamins;Extracellular matrix organization;Innate Immune System;Immune System;Metabolism;The canonical retinoid cycle in rods (twilight vision);Metabolism of vitamins and cofactors;Retinoid metabolism and transport;Non-integrin membrane-ECM interactions;G alpha (i) signalling events;Visual phototransduction;GPCR downstream signalling;FOXA2 and FOXA3 transcription factor networks (Consensus)

Recessive Scores

pRec
0.845

Intolerance Scores

loftool
0.0557
rvis_EVS
0.5
rvis_percentile_EVS
79.89

Haploinsufficiency Scores

pHI
0.599
hipred
N
hipred_score
0.457
ghis
0.431

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.869

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Ttr
Phenotype
cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); vision/eye phenotype; digestive/alimentary phenotype; renal/urinary system phenotype; homeostasis/metabolism phenotype;

Gene ontology

Biological process
retinoid metabolic process;purine nucleobase metabolic process;regulation of signaling receptor activity;extracellular matrix organization;retinol metabolic process;neutrophil degranulation;cellular protein metabolic process;thyroid hormone transport
Cellular component
extracellular region;extracellular space;protein-containing complex;azurophil granule lumen;extracellular exosome
Molecular function
hormone activity;protein binding;identical protein binding;protein heterodimerization activity;thyroid hormone binding